Delving Into Key Updates in MDS From ASH 2025

Amer Zeidan, MBBS, discusses current treatment approaches for patients with lower-risk MDS and ongoing challenges with available therapies.

Amer Zeidan, MBBS, discusses factors that can influence the initiation of treatment in lower-risk MDS.

Amer Zeidan, MBBS, details data from ASH 2025 on real-world outcomes with luspatercept in lower-risk MDS.

Amer Zeidan, MBBS, unpacks data from a post hoc analysis of the COMMANDS trial of luspatercept in lower-risk MDS.

Amer Zeidan, MBBS, breaks down other key data in lower-risk MDS to emerge from ASH 2025.

Amer Zeidan, MBBS, spotlights ongoing research to watch in higher-risk MDS after ASH 2025.